The ongoing evolution of SARS-CoV-2 into more easily transmissible and infectious variants
has sparked concern over the continued effectiveness of existing therapeutic antibodies and …

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages
that are more transmissible and resistant to currently approved antibody therapies poses a …

Antibody therapeutics for the treatment of COVID-19 have been highly successful. However,
the recent emergence of the Omicron variant has posed a challenge, as it evades detection …

The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of
the COVID-19 pandemic. Thus far, there is no approved therapeutic drug, specifically …

SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …

Abstract COVID-19 pathogen SARS-CoV-2 has infected hundreds of millions and caused
over 5 million deaths to date. Although multiple vaccines are available, breakthrough …

The emergence of SARS-CoV-2 variants that threaten the efficacy of existing vaccines and
therapeutic antibodies underscores the urgent need for new antibody-based tools that …

In vitro antibody selection against pathogens from naïve combinatorial libraries can yield
various classes of antigen-specific binders that are distinct from those evolved from natural …

Abstract SARS-CoV-2 Omicron variant XBB. 1.5 has shown extraordinary immune escape
even for fully vaccinated individuals. There are currently no approved antibodies that …

ABSTRACT SARS-CoV-2 neutralizing antibodies represent an important component of the
ongoing search for effective treatment of and protection against COVID-19. We report here …